AMRX: Amneal Pharmaceuticals, Inc. Stock

by  •  • Comments Off on AMRX: Amneal Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,715.31
Enterprise Value ($M) 5,155.73
Book Value ($M) -44.54
Book Value / Share -0.14
Price / Book -60.97
NCAV ($M) -1,958.18
NCAV / Share -6.32
Price / NCAV -1.39

Profitability (mra)
Return on Invested Capital (ROIC) -0.05
Return on Assets (ROA) -0.03
Return on Equity (ROE) -1.91

Liquidity (mrq)
Quick Ratio 0.86
Current Ratio 1.41

Balance Sheet (mrq) ($M)
Current Assets 1,587.81
Assets 3,501.45
Liabilities 3,545.98
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2,793.96
Operating Income 350.84
Net Income -116.89
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 295.10
Cash from Investing -63.00
Cash from Financing -211.79

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-10 13G/A UBS Group AG
01-23 13D/A Patel Dipan 7.70 -11.43
11-14 13G/A Mahesh Akram 8.80 -11.61
10-31 13D/A Patel Chirag K. 7.10 0.00
05-13 13D/A Patel Tushar Bhikhubhai 17.40 0.00
04-24 13G/A Fosun International Ltd 3.00 -50.02
2024-02-13 13G/A Vanguard Group Inc 4.45 4.55

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 203,652 1,662,597 12.25
2025-03-06 582,365 2,255,262 25.82
2025-03-05 264,745 1,920,674 13.78
2025-03-04 157,009 1,592,158 9.86

(click for more detail)

Similar Companies
AMGN – Amgen Inc. AMLX – Amylyx Pharmaceuticals, Inc.
AMPH – Amphastar Pharmaceuticals, Inc. ANAB – AnaptysBio, Inc.
ANNX – Annexon, Inc.


Financial data and stock pages provided by
Fintel.io